# Italy Chemicals Export Opportunities (HS 28-38) ![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp) > Yugalinks sector export playbook Explore Italy HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities. ## Overview - Exporter: Italy (ITA) - Sector: Chemicals - HS chapters: HS 28-38 - Latest trade year: 2024 - Sector exports: $29.5B - Products: 45 - Buyer markets: 25 - Average CAGR: +15.0% - Global sector size: $688.0B ## Product portfolio | Product | Global size | Your exports | Opportunity | CAGR | Markets | Share | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $247.0B | $17.9B | $70.4B | +11.4% | 13 | +5.4% | | HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $141.9B | $7.2B | $49.4B | +23.4% | 11 | +4.0% | | HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $20.8B | $2.5M | $36.2B | -3.6% | 3 | +0.0% | | HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $28.6B | $79.7M | $33.1B | +30.7% | 4 | +0.7% | | HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $19.4B | $74.0M | $22.9B | +3.0% | 3 | +0.4% | | HS 300220 - Vaccines: for human medicine | $25.9B | $1.6B | $18.9B | +37.2% | 5 | +3.7% | | HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $19.9B | $216.7M | $13.3B | +29.8% | 5 | +1.1% | | HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $25.3B | $489.7M | $12.9B | +12.8% | 4 | +2.8% | | HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $8.0B | $1.4M | $12.3B | +15.7% | 5 | +0.0% | | HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $13.4B | $341.2M | $11.6B | +34.6% | 5 | +1.9% | | HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $8.5B | $1.3M | $10.5B | +3.6% | 1 | +0.0% | | HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $6.8B | $23.0M | $9.5B | +11.5% | 2 | +0.3% | | HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $11.9B | $157.6M | $7.2B | +4.1% | 2 | +1.3% | | HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $5.3K | $6.7B | -7.8% | 1 | +0.0% | | HS 290243 - Cyclic hydrocarbons: p-xylene | $8.5B | $50.7K | $6.3B | +19.5% | 1 | +0.0% | | HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $4.7B | $15.8M | $6.1B | +5.1% | 3 | +0.3% | | HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $294.0M | $6.0B | +11.2% | 3 | +2.0% | | HS 293319 - Heterocyclic compounds: with nitrogen hetero-atom(s) only, containing an unfused pyrazole ring (whether or not hydrogenated) in the structure, other than henazone (antipyrin) and its derivatives | $2.6B | $48.6 | $5.1B | -22.7% | 1 | +0.0% | | HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $6.8B | $21.0K | $5.0B | +0.9% | 2 | +0.0% | | HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $5.9M | $4.8B | +32.4% | 1 | +0.1% | | HS 282200 - Cobalt oxides and hydroxides: commercial cobalt oxides | $2.4B | $39.8K | $4.6B | +18.7% | 1 | +0.0% | | HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $3.0B | $9.1M | $4.3B | +9.7% | 2 | +0.3% | | HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $9.7B | $116.6M | $3.9B | +35.4% | 1 | +1.2% | | HS 290110 - Acyclic hydrocarbons: saturated | $2.0B | $22.5K | $3.8B | +4.0% | 1 | +0.0% | | HS 283691 - Carbonates: lithium carbonate | $2.5B | $16.7K | $3.8B | +32.6% | 1 | +0.0% | | HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $4.5B | $26.1M | $3.7B | +10.8% | 2 | +0.5% | | HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $3.8B | $4.2M | $3.6B | +8.1% | 2 | +0.1% | | HS 281820 - Aluminium oxide: other than artificial corundum | $3.5B | $18.4K | $3.4B | +4.4% | 2 | +0.0% | | HS 282520 - Lithium oxide and hydroxide | $1.6B | $39.9 | $2.7B | -42.4% | 1 | +0.0% | | HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $59.4 | $2.4B | -41.7% | 1 | +0.0% | | HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $2.7B | $215.5M | $2.4B | +7.2% | 1 | +8.0% | | HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $16.1M | $2.3B | +60.9% | 1 | +1.2% | | HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $8.1M | $2.3B | +42.9% | 1 | +0.5% | | HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $6.5K | $2.2B | -1.5% | 1 | +0.0% | | HS 284590 - Isotopes (excluding those of heading no. 2844): compounds, inorganic or organic, of such isotopes, whether or not chemically defined | $1.1B | $74.5K | $1.9B | +15.8% | 1 | +0.0% | | HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $32.3M | $1.9B | +5.8% | 1 | +1.4% | | HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $79.2K | $1.9B | +0.4% | 1 | +0.0% | | HS 330300 - Perfumes and toilet waters | $5.1B | $680.5M | $1.8B | +12.5% | 1 | +13.3% | | HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $443.9 | $1.8B | -13.4% | 1 | +0.0% | | HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $23.4K | $1.8B | -0.4% | 1 | +0.0% | | HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $9.4M | $1.7B | +4.4% | 1 | +0.5% | | HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $7.2M | $1.7B | +18.8% | 1 | +0.8% | | HS 284690 - Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $25.2K | $1.5B | +44.7% | 1 | +0.0% | | HS 293219 - Heterocyclic compounds: with oxygen hetero-atom(s) only, containing an unfused furan ring (whether or not hydrogenated) in the structure, n.e.c. in item no. 2932.1 | $990.6M | $170.0K | $1.5B | +2.0% | 1 | +0.0% | | HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.6B | $41.8K | $1.4B | +14.7% | 1 | +0.0% | ## Best markets - USA, Puerto Rico and US Virgin Islands (USA): $131.3B calculated opportunity across 17 products. - China (CHN): $53.6B calculated opportunity across 17 products. - Slovenia (SVN): $42.7B calculated opportunity across 6 products. - Germany (DEU): $36.5B calculated opportunity across 12 products. - Switzerland, Liechtenstein (CHE): $24.5B calculated opportunity across 4 products. - Belgium (BEL): $22.0B calculated opportunity across 4 products. - Netherlands (NLD): $13.8B calculated opportunity across 4 products. - Republic of Korea (KOR): $10.9B calculated opportunity across 5 products. - Mexico (MEX): $9.3B calculated opportunity across 4 products. - Canada (CAN): $8.8B calculated opportunity across 4 products. - Japan (JPN): $8.8B calculated opportunity across 3 products. - United Kingdom (GBR): $7.1B calculated opportunity across 3 products. ## Growth stars - HS 290121: +60.9% average CAGR, $2.3B calculated opportunity. - HS 284690: +44.7% average CAGR, $1.5B calculated opportunity. - HS 282590: +42.9% average CAGR, $2.3B calculated opportunity. - HS 300220: +37.2% average CAGR, $18.9B calculated opportunity. - HS 330499: +35.4% average CAGR, $3.9B calculated opportunity. - HS 382600: +34.6% average CAGR, $11.6B calculated opportunity. - HS 283691: +32.6% average CAGR, $3.8B calculated opportunity. - HS 293379: +32.4% average CAGR, $4.8B calculated opportunity. - HS 300214: +30.7% average CAGR, $33.1B calculated opportunity. - HS 382499: +29.8% average CAGR, $13.3B calculated opportunity. ## Diversification opportunities - HS 300490: 13 buyer markets, $70.4B calculated opportunity. - HS 300215: 11 buyer markets, $49.4B calculated opportunity. - HS 300220: 5 buyer markets, $18.9B calculated opportunity. - HS 382499: 5 buyer markets, $13.3B calculated opportunity. - HS 284190: 5 buyer markets, $12.3B calculated opportunity. - HS 382600: 5 buyer markets, $11.6B calculated opportunity. - HS 300214: 4 buyer markets, $33.1B calculated opportunity. - HS 300212: 4 buyer markets, $12.9B calculated opportunity. - HS 293719: 3 buyer markets, $36.2B calculated opportunity. - HS 293359: 3 buyer markets, $22.9B calculated opportunity. ## Method Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology). ## Data sources - Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/) - CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf) This page presents derived Yugalinks views of reported observations and calculated indicators.